AzTrials
AzTrials

Intubation IntraesophagealOPTINIVNCT02530957

Non Invasive Ventilation Combined to High Flow Nasal Cannula Oxygen for Preoxygenation of Hypoxemic ICU Patients

A study testing Non invasive ventilation + High flow nasal cannula oxygen and Non invasive ventilation in people with Intubation Intraesophageal, run by University Hospital, Montpellier at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Tracheal intubation is a challenging procedure in Intensive Care Unit (ICU), associated with severe life threatening complications. To decrease these complications, preoxygenation is recommended. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Intubation Intraesophageal
What is being tested?
Non invasive ventilation + High flow nasal cannula oxygen and Non invasive ventilation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteFrance
Study dates
23 Jun 2015to 17 Mar 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult hypoxemic patients
  • Patients intubated in the ICU for acute respiratory failure (Hypoxemia is defined by the need of a FiO2>50% to maintain a SpO2>90% and a PaO2/FiO2 ratio<300 mmHg under mask oxygen therapy with a flow of 15L/min (measured during the 4 hours before inclusion)).

Who cannot join

  • non adult patients (age <18 years)
  • pregnant woman
  • protected persons
  • Patient intubated in case of cardio circulatory arrest
  • Patient with nasopharyngeal obstacle contraindicating the use of HNFC

Trial locations and contacts

1 site in 1 country.

France1 site
  • Centre Hospitalier Universitaire Montpellier, Saint Eloi

    Montpellier, Languedoc-Roussillon, 34295

Other trials in France

About this study

Official title: Comparison of Two Methods of Preoxygenation Before Oro Tracheal Intubation in the Hypoxemic Patient in Intensive Care Unit : Non Invasive Ventilation (NIV) + High Flow Nasal Cannula Oxygen Versus NIV Alone : a Randomized Controlled Study

Tracheal intubation is a challenging procedure in Intensive Care Unit (ICU), associated with severe life threatening complications. To decrease these complications, preoxygenation is recommended. Non invasive ventilation (NIV) increase effectiveness of preoxygenation, applying a positive end expiratory pressure (PEEP). High-flow nasal cannula oxygen (HFNC) improves oxygenation by increasing end-expiratory lung volume and has a potential of apneic oxygenation. The association of NIV and HFNC for preoxygenation in hypoxemic ICU patients has never been evaluated. The aim of this study is to determine if HFNC combined to NIV could have therapeutic advantages over NIV alone for preoxygenation in the ICU patients intubated for hypoxemic acute respiratory failure.

Read the detailed description

Patients admitted in Intensive Care Unit (ICU) often need respiratory support. Endotracheal intubation procedure in ICU is associated with severe life threatening complications. In order to decrease the incidence of complications including hypoxemia during intubation procedure, a preoxygenation is recommended, consisting in the administration of pure oxygen before intubation.

Recent data suggest that NIV use for preoxygenation of patients with acute respiratory failure is associated with less hypoxemia during intubation procedure than classic preoxygenation with facial mask. Indeed, associating Pressure Support (PS) with Positive end expiratory pressure (PEEP) limits the alveolar collapse and atelectasis formation. NIV is now used by a lot of of teams for preoxygenation of patients with acute respiratory failure in ICU.

However, although NIV is effective to reduce hypoxemia during intubation procedure, NIV mask has to be taken off after preoxygenation in order to allow the passage of the oro tracheal tube through the mouth. The hypoxemic patient does not receive oxygen during this period, which participates to the episodes of major hypoxemia during intubation.

In contrast, HFNC, which delivers high flow heated and humidified oxygen and air via nasal prongs at a prescribed fraction of inspired oxygen and a maximum flow of 60 L/min can be pursued during the intubation procedure. Some very recent studies suggest that HNFC could allow apneic oxygenation.

Although use of HFNC combined to NIV may have potential advantages over conventional NIV for preoxygenation before intubation in hypoxemic ICU patients, this technique of preoxygenation has never been assessed and benefit remains to be established.

The OPTINIV study aims to compare the effects of preoxygenation with combination of NIV and HFNC versus NIV alone on lowest oxygen saturation during intubation procedure of ICU patients intubated for acute respiratory failure.

Study design and population The OPTINIV trial is an investigator initiated multicenter randomized controlled two-arm blinded trial.

Local investigators screen consecutive patients intubated in ICU, with an acute respiratory failure (respiratory rate > 25/min) and hypoxemia. Hypoxemia is defined by the need of a fraction inspirated in oxygen (FiO2)>50% to maintain a saturation of arterial blood with oxygen as measured by pulse oximetry (SpO2)>90% and a partial pressure of oxygen in the arterial blood (PaO2)/FiO2 ratio<300 mmHg under mask oxygen therapy with a flow of 15L/min (measured during the 4 hours before inclusion).

Patients fulfilling one or more of the following criteria will not be included: nonadult patients (age <18 years), pregnant, protected persons, intubation in case of cardio circulatory arrest, nasopharyngeal obstacle contraindicating the use of HNFC.

Ethics and consent The Institutional Review Board of the University Hospital of Montpellier (France) approved the trial. By May 2015, the study had been approved by a central ethics committee (Committee for the Protection of Persons, Montpellier, France) with the registration number IDRCB 2015-A00708-41.

All patients or their next will asked for signed informed consent, as required by the institutional review board in accordance with the Declaration of Helsinki or emergency procedure allowed inclusion as a part of care in acute situation according the French Law.

Data collection The following data will be collected and registered before intubation: demographic data : age, sex, weight, height, date and hour of intubation, severity scores (Simplified Acute Physiologic Score (SAPS) II at admission, Sequential Organ Failure Assessment (SOFA) score on the day of the procedure), type of admission, reason of admission in ICU, indication of intubation, comorbidities, nature and number of operators, formation, fluid loading before intubation, arterial pressure and lowest saturation, therapeutic by vasopressor drugs or non invasive ventilation, predictive criteria of difficult intubation (including the MACOCHA score).

During the preoxygenation, will be recorded : need to change the method of preoxygenation and the reasons for changing, size of intubation tube, vital parameters : oxygen saturation at the beginning and at the end of the preoxygenation, lowest saturation, lowest and highest arterial pressure and heart rate, length and difficulty of preoxygenation.

During the intubation procedure, the following parameters will be collected : hypnotic and neuromuscular blocker used and dose, oxygen saturation at the beginning and at the end, lowest saturation, total length of intubation procedure, difficult intubation, number of operators, number of attempts, Cormack grade, traction force on the laryngoscope, Sellick manoeuver, occurrence of complications related to intubation.

After the intubation procedure (until one hour after): a thorax X-ray will be done, and arterial blood gases. Complications related to intubation will be collected.

Length of mechanical ventilation, length of stay in ICU, mortality at day 28 will be recorded.

Trial interventions Patients eligible for inclusion are randomly assigned to the interventional group or to the reference group. In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied. HFNC will applied along all the intubation procedure including the apnea period. In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) will be applied.

Outcomes Primary outcome variable is the lowest oxygen saturation collected by pulse oxymetry during the intubation procedure. The intubation procedure lasts from the beginning of the first laryngoscopy to the confirmation of the orotracheal intubation.

Secondary outcome variables are preoxygenation quality, complications related to intubation (severe : severe hypoxemia defined by lowest saturation < 80 %, severe cardiovascular collapse, defined as systolic blood pressure less than 65 mm Hg recorded at least one time or less than 90 mm Hg that lasted 30 minutes despite 500-1,000 ml of fluid loading (crystalloids or colloids solutions) or requiring introduction of vasoactive support, cardiac arrest, death during intubation; moderate: difficult intubation, arrhythmias, esophageal intubations, agitation, pulmonary aspiration, dental injuries), morbidity in ICU (length of stay, length of mechanical ventilation, mortality at 28 days).

Statistical analysis Quantitative variables will be expressed as means (standard deviation) or medians (interquartiles 25%-75%) and compared using the student t test or the Wilcoxon test as appropriate (Gaussian or non Gaussian variables). Qualitative variables will be compared using the chi 2 test or the Fisher test as appropriate.

A linear regression will be used to adjust the relation of lowest oxygen saturation during intubation procedure and group of inclusion. A multivariate model will be established.

A p-value of ≤ .05 will be considered statistically significant. The statistical analysis will be performed by the medical statistical department of the Montpellier University Hospital with the help of statistical software (SAS, version 9.3; SAS Institute; Cary, NC and R, version 2.14.1).

Being tested
Non invasive ventilation + High flow nasal cannula oxygen, Non invasive ventilation
Keywords
Intubation, Preoxygenation, Complications, Non invasive ventilation, High flow nasal cannula

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non invasive ventilation + High flow nasal cannula oxygenDevice

    In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.

  • Non invasive ventilationDevice

    In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.

Study groups in NCT02530957
Study groupRoleWhat they receive
InterventionalExperimentalIn the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
Receives: Device: Non invasive ventilation + High flow nasal cannula oxygen
ReferenceOtherIn the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
Receives: Device: Non invasive ventilation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lowest oxygen saturation

    Measured: 1 years

Secondary outcomes (1)
  1. Number of complications related to intubation

    Measured: 1 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2015 (estimated)
  2. Study start23 Jun 2015
  3. Primary completion28 Feb 2016
  4. Study completion17 Mar 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02530957
Sponsor's protocol ID
9543
Other IDs
2015-A00708-41
Acronym
OPTINIV
Status last verified
Apr 2017
First submitted
7 Aug 2015
Last updated
10 Apr 2017
Results posted
No
Data monitoring committee
No

Publications

  • De Jong A, Molinari N, Terzi N, Mongardon N, Arnal JM, Guitton C, Allaouchiche B, Paugam-Burtz C, Constantin JM, Lefrant JY, Leone M, Papazian L, Asehnoune K, Maziers N, Azoulay E, Pradel G, Jung B, Jaber S; AzuRea Network for the Frida-Rea Study Group. Early identification of patients at risk for difficult intubation in the intensive care unit: development and validation of the MACOCHA score in a multicenter cohort study. Am J Respir Crit Care Med. 2013 Apr 15;187(8):832-9. doi: 10.1164/rccm.201210-1851OC.

    PubMed 23348979
  • Jaber S, Amraoui J, Lefrant JY, Arich C, Cohendy R, Landreau L, Calvet Y, Capdevila X, Mahamat A, Eledjam JJ. Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study. Crit Care Med. 2006 Sep;34(9):2355-61. doi: 10.1097/01.CCM.0000233879.58720.87.

    PubMed 16850003
  • De Jong A, Jung B, Jaber S. Intubation in the ICU: we could improve our practice. Crit Care. 2014 Mar 18;18(2):209. doi: 10.1186/cc13776. No abstract available.

    PubMed 25029179
  • De Jong A, Futier E, Millot A, Coisel Y, Jung B, Chanques G, Baillard C, Jaber S. How to preoxygenate in operative room: healthy subjects and situations "at risk". Ann Fr Anesth Reanim. 2014 Jul-Aug;33(7-8):457-61. doi: 10.1016/j.annfar.2014.08.001. Epub 2014 Aug 29.

    PubMed 25168301
  • Baillard C, Fosse JP, Sebbane M, Chanques G, Vincent F, Courouble P, Cohen Y, Eledjam JJ, Adnet F, Jaber S. Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. Am J Respir Crit Care Med. 2006 Jul 15;174(2):171-7. doi: 10.1164/rccm.200509-1507OC. Epub 2006 Apr 20.

    PubMed 16627862
  • Jaber S, Michelet P, Chanques G. Role of non-invasive ventilation (NIV) in the perioperative period. Best Pract Res Clin Anaesthesiol. 2010 Jun;24(2):253-65. doi: 10.1016/j.bpa.2010.02.007.

    PubMed 20608561
  • Vourc'h M, Asfar P, Volteau C, Bachoumas K, Clavieras N, Egreteau PY, Asehnoune K, Mercat A, Reignier J, Jaber S, Prat G, Roquilly A, Brule N, Villers D, Bretonniere C, Guitton C. High-flow nasal cannula oxygen during endotracheal intubation in hypoxemic patients: a randomized controlled clinical trial. Intensive Care Med. 2015 Sep;41(9):1538-48. doi: 10.1007/s00134-015-3796-z. Epub 2015 Apr 14.

    PubMed 25869405
  • Miguel-Montanes R, Hajage D, Messika J, Bertrand F, Gaudry S, Rafat C, Labbe V, Dufour N, Jean-Baptiste S, Bedet A, Dreyfuss D, Ricard JD. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. Crit Care Med. 2015 Mar;43(3):574-83. doi: 10.1097/CCM.0000000000000743.

    PubMed 25479117
  • Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, Galia F, Futier E, Constantin JM, Jaber S. Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. Minerva Anestesiol. 2013 Dec;79(12):1344-55. Epub 2013 Jul 15.

    PubMed 23857440
  • Chanques G, Jaber S. [Unexpected progress of an old intensive care therapy, oxygen: towards more comfort and less mechanical ventilation...]. Rev Mal Respir. 2013 Oct;30(8):605-8. doi: 10.1016/j.rmr.2013.07.006. Epub 2013 Aug 27. No abstract available. French.

    PubMed 24182647
  • Hedenstierna G, Rothen HU. Atelectasis formation during anesthesia: causes and measures to prevent it. J Clin Monit Comput. 2000;16(5-6):329-35. doi: 10.1023/a:1011491231934.

    PubMed 12580216
  • Hedenstierna G, Edmark L. The effects of anesthesia and muscle paralysis on the respiratory system. Intensive Care Med. 2005 Oct;31(10):1327-35. doi: 10.1007/s00134-005-2761-7. Epub 2005 Aug 16.

    PubMed 16132894
  • Kolettas A, Grosomanidis V, Kolettas V, Zarogoulidis P, Tsakiridis K, Katsikogiannis N, Tsiouda T, Kiougioumtzi I, Machairiotis N, Drylis G, Kesisis G, Beleveslis T, Zarogoulidis K. Influence of apnoeic oxygenation in respiratory and circulatory system under general anaesthesia. J Thorac Dis. 2014 Mar;6 Suppl 1(Suppl 1):S116-45. doi: 10.3978/j.issn.2072-1439.2014.01.17.

    PubMed 24672687
  • Engstrom J, Hedenstierna G, Larsson A. Pharyngeal oxygen administration increases the time to serious desaturation at intubation in acute lung injury: an experimental study. Crit Care. 2010;14(3):R93. doi: 10.1186/cc9027. Epub 2010 May 24.

    PubMed 20497538
  • Griesdale DE, Bosma TL, Kurth T, Isac G, Chittock DR. Complications of endotracheal intubation in the critically ill. Intensive Care Med. 2008 Oct;34(10):1835-42. doi: 10.1007/s00134-008-1205-6. Epub 2008 Jul 5.

    PubMed 18604519

Questions about this trial

What is this clinical trial studying?

A study testing Non invasive ventilation + High flow nasal cannula oxygen and Non invasive ventilation in people with Intubation Intraesophageal, run by University Hospital, Montpellier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lowest oxygen saturation (time frame: 1 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02530957, which also lists 29 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2017; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in